Rat adjuvant arthritis as a model to test potential antirheumatic agents

Area of Science:

• Immunology
• Pharmacology
• Rheumatology

Background:

• Adjuvant arthritis is a model for rheumatoid arthritis.
• Understanding drug effects on immune responses is crucial.

Purpose of the Study:

• To compare the efficacy of immunomodulating drugs (CCA, d-penicillamine, thiabendazole) with established anti-inflammatory drugs (indomethacin, tolfenamic acid, prednisolone) in a rat model of adjuvant arthritis.
• To investigate the impact of d-penicillamine and complement inhibitors on arthritis progression.

Main Methods:

• Adjuvant arthritis was induced in Sprague-Dawley rats using Mycobacterium tuberculosis.
• Rats were treated with N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium (CCA), d-penicillamine, thiabendazole, indomethacin, tolfenamic acid, prednisolone, epsilon aminocaproic acid, and heparin.
• Arthritis severity was assessed to evaluate drug effects.

Main Results:

• All tested anti-inflammatory drugs (indomethacin, tolfenamic acid, prednisolone) were highly protective against adjuvant arthritis.
• Thiabendazole demonstrated a dose-related inhibitory effect on arthritis.
• D-penicillamine and complement inhibitors (epsilon aminocaproic acid, heparin) aggravated arthritis symptoms, with d-penicillamine showing enhanced effects upon pre-treatment.

Conclusions:

• The efficacy of immunomodulating drugs in adjuvant arthritis is dependent on dosage and treatment timing relative to disease onset.
• D-penicillamine and complement inhibition appear to exacerbate adjuvant arthritis, suggesting complex roles in immune-mediated inflammation.
• Thiabendazole warrants further investigation as a potential therapeutic agent for inflammatory arthritis.